24/04/2026
🚨 BIG NEWS for the future of longevity medicine.
The FDA has officially announced a public advisory committee meeting — scheduled for July 23–24, 2026 — to formally review some of the most talked-about peptides and regenerative compounds in the wellness world for inclusion on the 503A Bulk Drug Substances List.
On the table?
🔬 BPC-157 — gut healing, tissue repair, anti-inflammatory
🔬 TB-500 — cellular regeneration, recovery, flexibility
🔬 KPV — anti-inflammatory, gut & skin health
🔬 MOTs-C — metabolic optimization, longevity
🔬 Semax — cognitive enhancement, neuroprotection
🔬 Epitalon — anti-aging, telomere support
🔬 DSIP (Emideltide) — deep sleep, stress regulation
This is a landmark moment for science-driven wellness — and exactly the kind of innovation we've always believed in at RC WellMed.
At our boutique longevity practice, we don't follow trends. We follow the science. And the science is speaking loudly right now. 🧬
Stay tuned — we'll be watching this closely and keeping our community informed every step of the way.
📲 Questions about longevity therapies? Reach out or book your consultation at rcwellmed.com